The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Advisory Committee Tracker: Quiet August But Fall Looks Busy: Repros, Merck and Maybe DMD Sponsors Have Big Days Ahead Jul. 29, 2015
- 21st Century Cures and PDUFA VI: One Bill, Or Two? Jul. 28, 2015
- FDA Draft “Quality Metrics” Guidance: Agency Asks Whether to Include “Management Engagement” Metrics Jul. 27, 2015
See More Research Notes